Research programme: cancer therapeutics - LeuchemixAlternative Names: LC-913 series; LC812 series; LCVJ series; LCVJ2 series
Latest Information Update: 15 Oct 2008
At a glance
- Originator Leuchemix
- Mechanism of Action Tubulin polymerisation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours